Clinical trial
Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With…
NCT00411723 · Artielle ImmunoTherapeutics, Industry · Unknown status
Key facts
| NCT number | NCT00411723 |
|---|---|
| Title | Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis |
| Official title | Phase 1 Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis |
| Lead sponsor | Artielle ImmunoTherapeutics, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Chronic Progressive, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | RTL1000 (recombinant T cell receptor ligand), RTL1000 Placebo |
| Enrollment | 34 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Dec 14, 2006 |
| Last update posted | Feb 20, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: